AirXpanders closes $10 M investment round and initiates U.S. Clinical study
January 23, 2012
AirXpanders Inc., a company developing innovative products addressing the breast and burn reconstruction markets, secured $10 million in Series D financing. Investors include Vivo Ventures, GBS Venture Partners, Heron Capital and Prolog Ventures.
This round will fund the ongoing U.S. Investigational Device Exemption (IDE) study for the AeroForm™ Patient Controlled Tissue Expander System.
Scott Dodson, CEO, said the company has already seen "great success" in the IDE study, with no adverse events reported to date.
AirXpanders Announces First Commercial U.S. Procedure for AeroForm® Tissue Expander System for Breast Reconstruction
January 18, 2017
US FDA grants de novo clearance to AirXpanders' AeroForm Tissue Expander System for breast reconstruction
December 26, 2016
First Patient Treated in U.S. Randomized Trial of NeoChord’s, Off-Pump, Minimally Invasive Repair for Degenerative Mitral Regurgitation
November 9, 2016